Isoniazid-Induced Acute Liver Failure Requiring Liver Transplantation
Mariana Silva Almeida, Francisco Gomes, Maria do Rosário Ginga, Martinho Fernandes, Joana Cartucho · Cureus · 2022
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Cureus · Cureus, Inc. · article · 2022
Abstract
Tuberculosis (TB) is a contagious disease caused by the bacilli Mycobacterium tuberculosis complex. Currently, about a quarter of the world's population is infected with Mycobacterium tuberculosis. According to the World Health Organization, in 2018, Portugal had a TB incidence rate of about 24 cases per 100,000 inhabitants. It is estimated that 5-15% of individuals with latent TB infection progress to active TB. Isoniazid is one of the most widely used drugs for the treatment of active and latent TB. However, care must be taken with the possible development of toxicity, particularly hepatic.
The authors report a case of a 60-year-old woman diagnosed with latent TB who started therapy with isoniazid. Five months later, she developed acute liver failure secondary to the drug, requiring liver transplantation, with a favorable clinical outcome. Thus, we intend to alert to the potential toxicities of isoniazid, establishing follow-up strategies in patients on this therapy.
Open the resolved locator · 10.7759/cureus.32905
Metadata licence: OpenAlex metadata (CC0)